Previous close | 1.3600 |
Open | 1.3800 |
Bid | 1.3100 x 900 |
Ask | 1.3400 x 900 |
Day's range | 1.2900 - 1.4299 |
52-week range | 0.5400 - 5.2900 |
Volume | |
Avg. volume | 4,818,229 |
Market cap | 199.911M |
Beta (5Y monthly) | 1.96 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5900 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.45 |
Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders will doubtless be very grateful to see the share price up 125% in...
CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 5, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 6,188 shares of its common stock to one new employee, consisting of stock options to purchase 4,125 shares of common stock and restricted stock units (“RSUs”) covering 2,063 s
Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST (fecal microbiota spores, live-brpk) capsules. This transaction, when completed, supersedes any prior agreements between Nestlé and Seres concerning VOWST. Nestlé Health Science has been the lead commercialization party for the product since its l